| Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress |
Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101 |
globenewswire.com |
2025-05-14 13:30:00 |
Czytaj oryginał (ang.) |
| Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference |
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 11:00 a.m. |
globenewswire.com |
2025-05-13 11:00:00 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) |
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effective therapies that can treat the entire spectrum of disease. |
globenewswire.com |
2025-05-12 20:01:00 |
Czytaj oryginał (ang.) |
| BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates |
Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development. |
zacks.com |
2025-05-07 14:01:04 |
Czytaj oryginał (ang.) |
| Why Beam Therapeutics Stock Tanked on Tuesday |
Precision gene-editing company Beam Therapeutics (BEAM -19.68%) had a Tuesday to forget on the stock market. Following the release that morning of its latest set of quarterly results, the shares raced downwards to a more than 19% loss on the day. |
fool.com |
2025-05-06 21:05:15 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates |
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.21 per share a year ago. |
zacks.com |
2025-05-06 13:20:50 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights |
First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam's Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Accepted for Presentation at the European Hematology Association 2025 Congress in June Following Positive Initial Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Company Initiated Dosing of Fourth Cohort in Part A of Phase 1/2 Trial and Received Clearance of U.S. IND; Updated Data Expected to be Presented in Second Half of 2025 Ended First Quarter 2025 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities, Including Net Proceeds from $500 Million Financing; Cash Runway Expected to Support Operating Plans into 2028 CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2025 financial results and provided an update on corporate and pipeline progress across the company's hematology and genetic disease franchises. |
globenewswire.com |
2025-05-06 11:00:00 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress |
New Data Demonstrate Proportion of Corrected M-AAT Reached a Mean of 91% of Total AAT in Circulation at Day 28 Following BEAM-302 Treatment in 60 mg Cohort (n=3) |
globenewswire.com |
2025-04-05 11:00:00 |
Czytaj oryginał (ang.) |
| Power Ranking Our Top Stock Picks of 2025 |
Subscribers to Chart of the Week received this commentary on Sunday, March 30. |
schaeffersresearch.com |
2025-04-01 14:47:18 |
Czytaj oryginał (ang.) |
| Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard |
Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration. |
invezz.com |
2025-03-31 18:25:18 |
Czytaj oryginał (ang.) |
| BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance |
The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States. |
zacks.com |
2025-03-28 12:30:53 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration |
U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. |
globenewswire.com |
2025-03-27 18:01:00 |
Czytaj oryginał (ang.) |
| Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy |
Recently, BEAM reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. Unfortunately, they concurrently announced a $500 million equity offering, which may have caused concerns about near-term dilution. Still, BEAM-302 has innovative in vivo base editing technology that could potentially offer a one-time curative therapy for patients suffering from AATD. |
seekingalpha.com |
2025-03-21 15:13:44 |
Czytaj oryginał (ang.) |
| 3 Gene Therapy Stocks to Watch Amid Industry Turmoil |
Sarepta Therapeutics Inc (NASDAQ:SRPT) is down 23.2% to trade at $77.86 at last check, and earlier hit a 52-week low of $75.06. |
schaeffersresearch.com |
2025-03-18 17:21:23 |
Czytaj oryginał (ang.) |
| BEAM Down Despite Positive Initial Data From Genetic Disorder Study |
Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency. |
zacks.com |
2025-03-11 15:10:21 |
Czytaj oryginał (ang.) |
| Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity |
On Monday, Beam Therapeutics Inc. BEAM announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for alpha-1 antitrypsin deficiency (AATD) and for in vivo base editing. |
benzinga.com |
2025-03-10 11:07:08 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Announces Pricing of Underwritten Offering |
CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of an underwritten offering of 16,151,686 shares of its common stock at an offering price of $28.48 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant, before deducting underwriter discounts and commissions and estimated offering expenses. Each pre-funded warrant will have an exercise price of $0.01 per share, will be exercisable immediately and will be exercisable until exercised in full. Gross proceeds from the offering are expected to be approximately $500.0 million. All of the securities in the offering are to be sold by Beam Therapeutics. The offering is expected to close on or about March 11, 2025, subject to customary closing conditions. |
globenewswire.com |
2025-03-10 08:01:00 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation |
Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels |
globenewswire.com |
2025-03-10 08:00:00 |
Czytaj oryginał (ang.) |
| Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates |
BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development. |
zacks.com |
2025-02-26 13:45:24 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates |
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to earnings of $1.73 per share a year ago. |
zacks.com |
2025-02-25 11:15:31 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts |
Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial of BEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Expected to Initiate in Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type 1a in Early 2025 IND-enabling Studies of ESCAPE Nongenotoxic Conditioning Approach Ongoing; Healthy Volunteer Study of BEAM-103 Antibody Expected to Initiate by Year-end Ended Fourth Quarter 2024 with $850.7 Million in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into 2027 CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported fourth quarter and full year 2024 financial results and reiterated anticipated milestones across the company's hematology and genetic disease franchises. |
globenewswire.com |
2025-02-25 09:00:00 |
Czytaj oryginał (ang.) |
| Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences |
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: |
globenewswire.com |
2025-02-24 09:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 67.27% Upside in Beam Therapeutics (BEAM): Can the Stock Really Move This High? |
The average of price targets set by Wall Street analysts indicates a potential upside of 67.3% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-02-13 12:56:09 |
Czytaj oryginał (ang.) |
| Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year? |
Here is how Beam Therapeutics Inc. (BEAM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year. |
zacks.com |
2025-02-10 12:40:46 |
Czytaj oryginał (ang.) |
| Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference |
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:30 p.m. ET in New York. |
globenewswire.com |
2025-01-30 09:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 84.5% in Beam Therapeutics (BEAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-01-28 12:56:16 |
Czytaj oryginał (ang.) |
| Is it a Good Idea to Invest in Beam Therapeutics Stock Now? |
Here, we discuss some reasons why investing in BEAM stock now may turn out to be a prudent move. |
zacks.com |
2025-01-24 13:40:15 |
Czytaj oryginał (ang.) |
| Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR |
CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in an oral presentation at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) taking place February 12 – 15, 2025, in Honolulu, Hawaii. |
globenewswire.com |
2025-01-23 09:00:00 |
Czytaj oryginał (ang.) |
| Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now? |
Beam Therapeutics (BEAM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. |
zacks.com |
2025-01-13 13:41:14 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts |
More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025 |
globenewswire.com |
2025-01-13 09:00:00 |
Czytaj oryginał (ang.) |
| 2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy |
Beam Therapeutics (BEAM) Gene editing firm Beam Therapeutics is developing its own pipeline with base editing as its foundation technology, a technique that changes a single DNA or RNA base without cutting the DNA strand. |
schaeffersresearch.com |
2025-01-10 13:30:04 |
Czytaj oryginał (ang.) |
| 5 Biotech Breakthrough Stocks to Watch in 2025 |
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services. |
zacks.com |
2024-12-23 12:40:34 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up |
BEAM appoints Sravan K. Emany as its new chief financial officer, effective Dec. 19. |
zacks.com |
2024-12-09 11:25:23 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting |
NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F |
globenewswire.com |
2024-12-08 15:45:00 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting |
All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to |
globenewswire.com |
2024-12-07 13:30:00 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer |
CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. |
globenewswire.com |
2024-12-06 09:00:00 |
Czytaj oryginał (ang.) |
| Why Is Beam Therapeutics (BEAM) Down 2.3% Since Last Earnings Report? |
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-05 14:36:14 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader |
CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., Inc., to its board of directors. Mr. Guindo is a seasoned executive in the pharmaceutical industry and has been a key leader at Merck for more than 25 years, where he held senior executive roles spanning global strategy, commercial operations and leadership in healthcare solutions. |
globenewswire.com |
2024-12-04 09:00:00 |
Czytaj oryginał (ang.) |
| Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference |
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. GMT in London. |
globenewswire.com |
2024-11-12 18:01:00 |
Czytaj oryginał (ang.) |
| Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch |
Beam Therapeutics Inc. will present additional data from phase 1/2 BEACON study, using BEAM-101 for the treatment of patients with SCD at the upcoming ASH Annual Meeting on December 7th - 10th of 2024. ESCAPE technology, looking to provide non-genotoxic conditioning for HSCT patients, is to be presented at the upcoming ASH 2024 Annual Meeting. The global Sickle Cell Disease treatment market size is projected to grow to $9.84 billion by 2030. |
seekingalpha.com |
2024-11-07 16:25:15 |
Czytaj oryginał (ang.) |
| Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates |
BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development. |
zacks.com |
2024-11-06 14:41:36 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript |
Beam Therapeutics Inc (NASDAQ:BEAM ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Holly Manning - Vice President of Investor Relations & External Communications John Evans - Chief Executive Officer Giuseppe Ciaramella - President Amy Simon - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Dae Gon Ha - Stifel Eric Joseph - JPMorgan Kostas Biliouris - BMO Capital Markets Samantha Semenkow - Citi Sami Corwin - William Blair Luca Issi - RBC Capital Michael Yee - Jefferies Rick Bienkowski - Cantor Fitzgerald Mani Foroohar - Leerink Partners Operator Good morning, and welcome to the Beam Therapeutics Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-05 13:54:13 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates |
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.22 per share a year ago. |
zacks.com |
2024-11-05 10:42:18 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs |
Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting |
globenewswire.com |
2024-11-05 08:30:00 |
Czytaj oryginał (ang.) |
| Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting |
CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company's abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH). |
globenewswire.com |
2024-10-29 08:30:00 |
Czytaj oryginał (ang.) |
| Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report? |
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-09-05 16:36:40 |
Czytaj oryginał (ang.) |
| 3 Gene Editing Stocks with Potential to Transform Medicine |
Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutation. |
investorplace.com |
2024-08-09 14:19:58 |
Czytaj oryginał (ang.) |
| Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss |
Beam Therapeutics (BEAM) reports mixed second-quarter results. The company remains focused on pipeline development. |
zacks.com |
2024-08-07 15:52:11 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates |
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.08 per share a year ago. |
zacks.com |
2024-08-06 12:46:08 |
Czytaj oryginał (ang.) |
| Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results |
U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) |
globenewswire.com |
2024-08-06 10:30:00 |
Czytaj oryginał (ang.) |
| Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock? |
Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-07-26 12:45:23 |
Czytaj oryginał (ang.) |